Related Experiment Video
Updated: Jun 16, 2026
08:27
Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
Galantamine for Alzheimer's disease.
David Prvulovic1, Harald Hampel, Johannes Pantel
1Johann Wolfgang Goethe-University of Frankfurt, Deptartment of Psychiatry, Psychosomatics and Psychotherapy, Heinrich-Hoffmann-Strasse 10, Frankfurt, Germany. David.Prvulovic@kgu.de
Expert Opinion on Drug Metabolism & Toxicology
|February 2, 2010
Summary
Galantamine, a cholinesterase inhibitor, effectively treats Alzheimer's disease (AD) by improving cognition and daily functioning. Its efficacy and safety are comparable to other AD medications, establishing it as a first-line treatment.
Area of Science:
- Neuroscience
- Pharmacology
- Geriatrics
Background:
- Alzheimer's disease (AD) is a leading cause of age-related neurodegeneration, impacting cognition and daily function.
- The central cholinergic system plays a crucial role in memory and cognition, and is affected early in AD.
Purpose of the Study:
- To review the rationale for cholinergic treatment in AD.
- To detail the chemistry, pharmacology, clinical efficacy, safety, and tolerability of galantamine.
- To explore potential uses of galantamine beyond AD.
Main Methods:
- Systematic review of placebo-controlled studies.
- Analysis of meta-analyses on galantamine.
- Review of galantamine's pharmacological profile and clinical trial data.
Main Results:
- Galantamine demonstrates clinical efficacy in improving cognitive performance, daily living activities, and behavioral symptoms in AD patients.
- Its safety and tolerability profile are comparable to other cholinesterase inhibitors.
- Galantamine offers a 6-month improvement and stabilization period for AD symptoms.
Conclusions:
- Galantamine is a key treatment for mild-to-moderate Alzheimer's disease.
- It provides significant benefits for cognitive and functional aspects of AD.
- Galantamine remains a standard first-line therapy for AD in the absence of superior alternatives.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Cholinergic Antagonists: Therapeutic Uses
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...